ICIs targeting PD-1 (e.g., pembrolizumab, nivolumab) and PD-L1 (e.g., atezolizumab, avelumab, durvalumab) have revolutionized the treatment of metastatic BC, particularly in patients with cisplatin-resistant disease.182. This evidence concerns the gene PDCD1 and breast cancer.